Back to Journals » Biologics: Targets and Therapy » Volume 7 » default
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (501)
- Volume 18, 2024 (5)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 7, 2013
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M
Biologics: Targets and Therapy 2013, 7:265-266
Published Date: 6 December 2013
Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
Mathieu S, Couderc M, Glace B, Pereira B, Tournadre A, Dubost JJ, Soubrier M
Biologics: Targets and Therapy 2013, 7:259-264
Published Date: 2 December 2013
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action
Damal K, Stoker E, Foley JF
Biologics: Targets and Therapy 2013, 7:247-258
Published Date: 27 November 2013
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
Kaushik T, Yaqoob MM
Biologics: Targets and Therapy 2013, 7:243-246
Published Date: 11 November 2013
Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus
Ideno S, Sakai K, Yunoki M, Kubota-Koketsu R, Inoue Y, Nakamura S, Yasunaga T, Okuno Y, Ikuta K
Biologics: Targets and Therapy 2013, 7:233-241
Published Date: 5 November 2013
Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Keohane C, Radia DH, Harrison CN
Biologics: Targets and Therapy 2013, 7:231-232
Published Date: 31 October 2013
Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck
Yang H, Diao LQ, Shi M, Ma R, Wang JH, Li JP, Xiao F, Xue Y, Xu M, Zhou B
Biologics: Targets and Therapy 2013, 7:223-229
Published Date: 18 October 2013
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
Franz DN
Biologics: Targets and Therapy 2013, 7:211-221
Published Date: 10 October 2013
Clinical utility of asthma biomarkers: from bench to bedside
Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L
Biologics: Targets and Therapy 2013, 7:199-210
Published Date: 29 August 2013
Treatment and management of myelofibrosis in the era of JAK inhibitors
Keohane C, Radia DH, Harrison CN
Biologics: Targets and Therapy 2013, 7:189-198
Published Date: 20 August 2013
Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus
Pipattanaboon C, Sasaki T, Nishimura M, Setthapramote C, Pitaksajjakul P, Leaungwutiwong P, Limkittikul K, Puiprom O, Sasayama M, Chaichana P, Okabayashi T, Kurosu T, Ono K, Ramasoota P, Ikuta K
Biologics: Targets and Therapy 2013, 7:175-187
Published Date: 15 August 2013
Erythropoiesis stimulating agents approaches to modulate activity
Sinclair AM
Biologics: Targets and Therapy 2013, 7:161-174
Published Date: 3 July 2013
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
Bennett J, Dubois C
Biologics: Targets and Therapy 2013, 7:149-159
Published Date: 19 June 2013
Tivozanib in the treatment of renal cell carcinoma
Hepgur M, Sadeghi S, Dorff TB, Quinn DI
Biologics: Targets and Therapy 2013, 7:139-148
Published Date: 11 June 2013
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
Reuss R
Biologics: Targets and Therapy 2013, 7:131-138
Published Date: 29 May 2013
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
Gledhill T, Bodger K
Biologics: Targets and Therapy 2013, 7:123-130
Published Date: 23 May 2013
Bosutinib in the management of chronic myelogenous leukemia
Keller-von Amsberg G, Schafhausen P
Biologics: Targets and Therapy 2013, 7:115-122
Published Date: 6 May 2013
Hereditary angioedema: epidemiology, management, and role of icatibant
Ghazi A, Grant JA
Biologics: Targets and Therapy 2013, 7:103-113
Published Date: 3 May 2013
Clinical use of crizotinib for the treatment of non-small cell lung cancer
Roberts PJ
Biologics: Targets and Therapy 2013, 7:91-101
Published Date: 26 April 2013
Cetuximab: its unique place in head and neck cancer treatment
Specenier P, Vermorken JB
Biologics: Targets and Therapy 2013, 7:77-90
Published Date: 15 April 2013
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F
Biologics: Targets and Therapy 2013, 7:69-75
Published Date: 15 March 2013
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
D'Arcangelo M, Cappuzzo F
Biologics: Targets and Therapy 2013, 7:61-68
Published Date: 3 March 2013
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Ververis K, Hiong A, Karagiannis TC, Licciardi PV
Biologics: Targets and Therapy 2013, 7:47-60
Published Date: 25 February 2013
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
Ansari J, Hussain SA, Ansari A, Glaholm J
Biologics: Targets and Therapy 2013, 7:39-46
Published Date: 28 February 2013
Treatment of hemophilia B: focus on recombinant factor IX
Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C
Biologics: Targets and Therapy 2013, 7:33-38
Published Date: 12 February 2013
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
Nooka A, Gleason C, Casbourne D, Lonial S
Biologics: Targets and Therapy 2013, 7:13-32
Published Date: 30 January 2013
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Walsh GM
Biologics: Targets and Therapy 2013, 7:7-11
Published Date: 9 January 2013
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C
Biologics: Targets and Therapy 2013, 7:1-6
Published Date: 4 January 2013